Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial
- Citation:
- Annals of Oncology vol 30 (Supplement_3) iii65–iii71
- Meeting Instance:
- ESMO Breast 2019
- Year:
- 2019
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3181
- Pharmas:
- GSK/Novartis
- Grants:
- Corr. Author:
- Authors:
- D. Eiger N. F. Ponde D. Agbor-Tarh Alvaro Moreno-Aspitia Martine Piccart Richard Rodeheffer Michael Ewers Thomas Suter E. de Azambuja
- Networks:
- LAPS-MN026
- Study
- NCCTG-N063D
- Multiple Studies, or Legacy Studies in Alliance Study:
- ALTTO
- Phases:
- 3, 3
- Keywords:
- HER2 positive breast cancer; cardio-toxicity; lapatinib; trastuzumab